Media Summary: Off-the-shelf CAR T could help offer this therapy to more people. In this highlight of Lung Cancer Living Room™, Danielle Hicks, Chief Patient Officer at GO2 for Lung Cancer, hosts Moffitt's physician team includes cancer surgeons, medical oncologists, radiation oncologists, radiologists, pathologists and more, ...

Asco 2024 Dr Fred Locke Discusses Immunotherapy - Detailed Analysis & Overview

Off-the-shelf CAR T could help offer this therapy to more people. In this highlight of Lung Cancer Living Room™, Danielle Hicks, Chief Patient Officer at GO2 for Lung Cancer, hosts Moffitt's physician team includes cancer surgeons, medical oncologists, radiation oncologists, radiologists, pathologists and more, ... Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at Xiuning Le, MD, PhD, of the University of Texas MD Anderson Cancer Center, joined Lung Cancers Today to Association of high baseline metabolic tumor volume with response following axicabtagene ciloleucel in refractory large B-cell ...

David Braun, MD, PhD, Yale School of Medicine, New Haven, CT, Meredith McKean, MD, MPH, Sarah Cannon Research Institute, Nashville, TN, gives an overview of key melanoma trials at the ...

Photo Gallery

ASCO 2024: Dr. Fred Locke Discusses Immunotherapy
Dr. Frederick Locke at ASCO 2022: Abstract No. 7565
Dr. Frederick Locke on the Latest in Cellular Immunotherapy
ASCO 2021 - Fred Locke, MD - Abstract 2529
Immunotherapy Treatment for Cancer: The Inspiring Story of Dimas and Dr. Locke
ASCO 2024: Immunotherapy for Limited-Stage Small Cell Lung Cancer
Frederick Locke, MD-  Blood & Marrow Transplant and Cellular Immunotherapy
ASCO 2021 Lung Recap: FDA Analysis of Immunotherapy With or Without Chemo in Adv NSCLC and Low PDL-1
ASCO 2025 Updates in Lung Cancer: From ADCs to Neoadjuvant Therapies
Can We Make Immunotherapy Work for EVERY Patient?
SITC 2024: Elsa Flores, PhD Discusses New Advancements for Immunotherapy
ASCO 2019: Frederick Locke, MD Abstract - TPS5596
Sponsored
Sponsored
View Detailed Profile
ASCO 2024: Dr. Fred Locke Discusses Immunotherapy

ASCO 2024: Dr. Fred Locke Discusses Immunotherapy

Moffitt Cancer Center's

Dr. Frederick Locke at ASCO 2022: Abstract No. 7565

Dr. Frederick Locke at ASCO 2022: Abstract No. 7565

Dr

Sponsored
Dr. Frederick Locke on the Latest in Cellular Immunotherapy

Dr. Frederick Locke on the Latest in Cellular Immunotherapy

Cellular

ASCO 2021 - Fred Locke, MD - Abstract 2529

ASCO 2021 - Fred Locke, MD - Abstract 2529

Off-the-shelf CAR T could help offer this therapy to more people.

Immunotherapy Treatment for Cancer: The Inspiring Story of Dimas and Dr. Locke

Immunotherapy Treatment for Cancer: The Inspiring Story of Dimas and Dr. Locke

At Moffitt Cancer Center, cutting-edge

Sponsored
ASCO 2024: Immunotherapy for Limited-Stage Small Cell Lung Cancer

ASCO 2024: Immunotherapy for Limited-Stage Small Cell Lung Cancer

In this highlight of Lung Cancer Living Room™, Danielle Hicks, Chief Patient Officer at GO2 for Lung Cancer, hosts

Frederick Locke, MD-  Blood & Marrow Transplant and Cellular Immunotherapy

Frederick Locke, MD- Blood & Marrow Transplant and Cellular Immunotherapy

Moffitt's physician team includes cancer surgeons, medical oncologists, radiation oncologists, radiologists, pathologists and more, ...

ASCO 2021 Lung Recap: FDA Analysis of Immunotherapy With or Without Chemo in Adv NSCLC and Low PDL-1

ASCO 2021 Lung Recap: FDA Analysis of Immunotherapy With or Without Chemo in Adv NSCLC and Low PDL-1

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at

ASCO 2025 Updates in Lung Cancer: From ADCs to Neoadjuvant Therapies

ASCO 2025 Updates in Lung Cancer: From ADCs to Neoadjuvant Therapies

Xiuning Le, MD, PhD, of the University of Texas MD Anderson Cancer Center, joined Lung Cancers Today to

Can We Make Immunotherapy Work for EVERY Patient?

Can We Make Immunotherapy Work for EVERY Patient?

In this episode,

SITC 2024: Elsa Flores, PhD Discusses New Advancements for Immunotherapy

SITC 2024: Elsa Flores, PhD Discusses New Advancements for Immunotherapy

At #SITC24, Elsa Flores, PhD

ASCO 2019: Frederick Locke, MD Abstract - TPS5596

ASCO 2019: Frederick Locke, MD Abstract - TPS5596

Association of high baseline metabolic tumor volume with response following axicabtagene ciloleucel in refractory large B-cell ...

Doris Hansen, MD and Fred Locke, MD at Cell Coast Conference 2024

Doris Hansen, MD and Fred Locke, MD at Cell Coast Conference 2024

During #CellCoast24, Doris Hansen, MD

ASCO 2024: Dr Bruna Pellini Discusses Lung Cancer Advances

ASCO 2024: Dr Bruna Pellini Discusses Lung Cancer Advances

Moffitt Cancer Center's

ASCO GU 2024: immunotherapy highlights in kidney cancer

ASCO GU 2024: immunotherapy highlights in kidney cancer

David Braun, MD, PhD, Yale School of Medicine, New Haven, CT,

Joshua Brody on Epcoritamab Immunotherapy for DLBCL | ASCO 2024

Joshua Brody on Epcoritamab Immunotherapy for DLBCL | ASCO 2024

In this episode of OncoDaily,

Frederick Locke, MD, discusses details from the ZUMA-9 clinical study presented at ASH 2020

Frederick Locke, MD, discusses details from the ZUMA-9 clinical study presented at ASH 2020

Dr

Melanoma trials at ASCO 2024: KEYMAKER-U02A, IMC-F106 and SC-682

Melanoma trials at ASCO 2024: KEYMAKER-U02A, IMC-F106 and SC-682

Meredith McKean, MD, MPH, Sarah Cannon Research Institute, Nashville, TN, gives an overview of key melanoma trials at the ...

ASCO 2024: Dr Eric Haura Discusses Lung Cancer

ASCO 2024: Dr Eric Haura Discusses Lung Cancer

Eric Haura, MD joins Patrick Hwu, MD to